PHA ACE2 soluble ace2
(Die Seite wurde neu angelegt: „{{up|Target ACE2, Spike protein}} {{tp|p=32391299|t=2020. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.|pdf=|usr=008}…“) |
|||
| Zeile 7: | Zeile 7: | ||
{{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}} | {{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}} | ||
{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}} | {{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32631373|t=2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.|pdf=|usr=012}} | ||
| + | {{tp|p=32663051|t=2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.|pdf=|usr=014}} | ||
| + | {{tp|p=32735992|t=2020. Design of an engineered ACE2 as a novel therapeutics against COVID-19.|pdf=|usr=017}} | ||
| + | {{tp|p=32753553|t=2020. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.|pdf=|usr=017}} | ||
| + | {{tp|p=32756606|t=2020. Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain.|pdf=|usr=017}} | ||
| + | {{tp|p=32804015|t=2020. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.|pdf=|usr=019}} | ||
| + | {{tp|p=32850978|t=2020. Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19.|pdf=|usr=018}} | ||
| + | {{tp|p=32864572|t=2020. Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure.|pdf=|usr=019}} | ||
| + | {{tp|p=32938937|t=2020. Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design.|pdf=|usr=019}} | ||
| + | {{tp|p=32941783|t=2020. The Inhibitory Effect of a Coronavirus Spike Protein Fragment with ACE2.|pdf=|usr=019}} | ||
| + | {{tp|p=33080267|t=2020. Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.|pdf=|usr=020}} | ||
| + | {{tp|p=33093202|t=2020. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.|pdf=|usr=020}} | ||
| + | {{tp|p=33118012|t=2020. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.|pdf=|usr=020}} | ||
| + | {{tp|p=33131609|t=2020. Human recombinant soluble ACE2 in severe COVID-19.|pdf=|usr=020}} | ||
| + | {{tp|p=33144557|t=2020. Outsmarting SARS-CoV-2 by empowering a decoy ACE2.|pdf=|usr=020}} | ||
| + | {{tp|p=33144565|t=2020. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19.|pdf=|usr=020}} | ||
| + | {{tp|p=33154107|t=2020. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2.|pdf=|usr=020}} | ||
| + | {{tp|p=33177651|t=2020. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection.|pdf=|usr=020}} | ||
| + | {{tp|p=33326798|t=?. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.|pdf=|usr=023}} | ||
| + | {{tp|p=C7720268|t=2020. A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking.|pdf=|usr=023}} | ||
Aktuelle Version vom 27. April 2021, 18:27 Uhr
| Target ACE2, Spike protein |
32391299 2020. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.
32410690 2020. Age and sex differences in soluble ACE2 may give insights for COVID-19.
32396773 2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
32398309 2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?
32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
32631373 2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.
32663051 2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.
32735992 2020. Design of an engineered ACE2 as a novel therapeutics against COVID-19.
32753553 2020. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
32756606 2020. Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain.
32804015 2020. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.
32850978 2020. Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19.
32864572 2020. Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure.
32938937 2020. Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design.
32941783 2020. The Inhibitory Effect of a Coronavirus Spike Protein Fragment with ACE2.
33080267 2020. Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.
33093202 2020. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
33118012 2020. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.
33131609 2020. Human recombinant soluble ACE2 in severe COVID-19.
33144557 2020. Outsmarting SARS-CoV-2 by empowering a decoy ACE2.
33144565 2020. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19.
33154107 2020. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2.
33177651 2020. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection.
33326798 ?. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
C7720268 2020. A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking.
